ArticleBMC infectious diseases2026
Changes in antimicrobial resistance of staphylococci isolated from bloodstream infection and the impact of COVID-19.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the changes in antimicrobial resistance of Staphylococcus aureus (S. aureus) and coagulase-negative staphylococci (CoNS) in bloodstream infections (BSIs) between 2018 and 2024, and to assess temporal associations with the COVID-19 pandemic.
methodsA total of 575 S. aureus and 1,014 CoNS isolates from blood cultures were retrospectively reviewed. To define true CoNS BSI, we applied clinical criteria (≥ 2 positive bottles with same species, or 1 positive bottle with clinical signs + central line + targeted therapy). Demographic characteristics and resistance rates to 15 antimicrobial agents were compared using chi-square (χ
resultsCoNS infections were more common in minors (0-17 years: 31.3%) and the elderly (≥ 80 years: 13.7%), while S. aureus predominated in adults 18-65 years (51.8%). CoNS exhibited higher resistance rates than S. aureus to oxacillin (75.2% vs. 30.5%, p < 0.001), ciprofloxacin (42.8% vs. 17.5%, p < 0.001) and erythromycin (82.2% vs. 56.1%, p < 0.001). Methicillin-resistant CoNS (MRCNS) detection rates exceeding 70% throughout. Penicillin G resistance in S. aureus increased from 87.1% (95% CI 78.0-93.0) in 2018 to 100% (95% CI 92.5-100) in 2024 (nominal P < 0.05, but not significant after correction). Following the pandemic onset, resistance rates to penicillin G, clindamycin, and ciprofloxacin further increased in both groups. After Bonferroni correction, the pandemic-period resistance rate increases of penicillin G, oxacillin, clindamycin, and erythromycin for S. aureus remained significant, while those for CoNS did not. No resistance to linezolid, vancomycin, or tigecycline was detected.
conclusionStaphylococci resistance in blood isolates has intensified, with temporal associations observed during the Coronavirus Disease 2019 (COVID-19) pandemic. Clinicians should reconsider empirical oxacillin use given persistently high methicillin resistance. Ongoing surveillance and antimicrobial stewardship are essential. Causal attribution is not possible due to uncontrolled confounders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.